about
Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximabRenal cell cancer: overview of the current therapeutic landscape.Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes.Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens.Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience.Treatment modalities in primary gastric lymphoma: the effect of rituximab and surgical treatment. A study by the Anatolian Society of Medical Oncology.Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience.Signal transducer and activator of transcription proteins in leukemias.Management of brain metastases from non-small cell lung cancer.Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma.Targeting signal transducer and activator of transcription signaling pathway in leukemias.Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma.Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experience.Malignancies diagnosed during pregnancy and treated with chemotherapy or other modalities (review of 27 cases): multicenter experiences.A previously unreported malignancy of the thyroid.Clear cell adenocarcinoma of the uterine cervix: a case report and review of the literature.Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab.Liver metastases from adenocarcinomas of unknown primary site: management and prognosis in 68 consecutive patients.Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish populationSynchronous testicular liposarcoma and prostate adenocarcinoma: a case report.Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancerIsolated primary lymphomatoid granulomatosis of central nervous system.Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens.Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab.Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients.Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: a multicentric Turkish Oncology Group (TOG) trial.Non-gestational uterine choriocarcinoma in a postmenopausal woman.Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancer.Coexistence Hodgkin's lymphoma and colonic adenocarcinoma: a case report.Gemcitabine-induced acute coronary syndrome: a case report.Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment.The results of three different treatment modalities in patients with locally advanced nasopharyngeal carcinoma.Prognostic factors in gastrointestinal stromal tumors: multicenter experience of 333 cases from Turkey.Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer.Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer.Factors Influencing Chemotherapy Goal Perception in Newly Diagnosed Cancer Patients.Assessment of right ventricular functions during cancer chemotherapy.Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus.
P50
Q28256567-2A3113E9-22EC-4EDF-9D99-8E5461192E8FQ30248354-39A238D8-1505-4677-B6B4-EC4CD9AF11E0Q33378298-336ED32E-5AC0-4F16-BCBD-0AABCA306874Q33386661-59C85B18-06AC-49B8-8FED-A3A0D5511AD9Q33398373-236E8D6D-5910-465D-B93F-378C14F2F35AQ34226740-A2E549ED-B813-4321-BA35-68D5727F8D8FQ34656707-5B5636D8-F67B-46B3-B3CA-9DD7D05DB4DEQ35024969-93984641-369E-456D-A1A3-54DC404CEE6DQ35541331-292644D1-A85D-4354-BAB1-81DF18656CCEQ36029954-8B03C610-83C6-42BD-8430-04537306CE46Q37347522-C631AEEA-88DC-4A82-A5F6-39920EA9EAB5Q37388043-35F5573E-9F9A-4AA2-82D8-93809429916EQ37677684-963BF498-21AD-4078-9E91-AB676D31C68EQ37802826-168D509C-E13B-4E90-BA4D-9A96BB5C0158Q37898558-CA8CE2A3-9D9D-4638-BA6A-76F7131BA012Q38106588-66DBA481-B5B0-4451-9911-7FBEC2AA1EC7Q40956681-FD6B6AAA-3536-4A33-B346-8C8071BB1CF4Q41355606-64CA061D-76BB-4C36-BCEC-62C87DC36C88Q41639995-ED528857-85AB-4919-A9E6-200C0571CE33Q41900890-C0920C92-0233-4684-968D-C1E9C0C6F789Q42059647-08A7A562-07B2-48AB-A237-0E5C291F1888Q42154372-F9BBA9A0-543A-4E69-A794-FF7E199C64DEQ43227528-514EF201-FA6A-4260-AA08-AC6717AF891BQ43610805-D5F689AF-C708-46C1-90C6-392585D0C524Q43901945-054AE2E7-2404-4F0F-A2D4-48C547AF3124Q44470469-9F93AB3D-E0F2-4B62-81FE-A94145F59655Q44664869-D0DE7778-B286-4B60-9FCB-94B2D4544372Q45254469-DC0BD99D-41C2-4537-95A6-17739FFAE862Q45952260-0543EB60-0DC2-49A5-883D-431E8DE95F43Q46109465-0E89DC1A-6827-4BD5-9EC0-56416FE145AAQ46127045-3911DF9C-9FA4-46B2-A00C-9C19BD48ADBEQ46211604-406E22A3-E019-4237-AC12-D2B67FB7C1EBQ46544778-4956C457-8EF6-4338-8BD8-7E6D0A9C735AQ46849880-0317AD61-1F12-4342-9A0F-7D1284366685Q46893138-C318C3BF-609E-43F3-813A-EB79C58A4E45Q46965894-5B4D2C8D-ABA2-4A16-A241-88EB3B20D681Q47590609-B9987CBA-40B4-4CF5-ACB6-15296DFE57B1Q47719912-1F18D907-EE13-4913-B804-D9861AD11FA1Q48924646-CA2B979E-1E83-40D2-AB3B-50AE468CEBE0Q50152043-D34F90E4-2D6A-46CF-A73F-5C310E49E1E2
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mustafa Benekli
@ast
Mustafa Benekli
@en
Mustafa Benekli
@es
Mustafa Benekli
@nl
type
label
Mustafa Benekli
@ast
Mustafa Benekli
@en
Mustafa Benekli
@es
Mustafa Benekli
@nl
prefLabel
Mustafa Benekli
@ast
Mustafa Benekli
@en
Mustafa Benekli
@es
Mustafa Benekli
@nl
P106
P1153
7003865624
P31
P496
0000-0003-3184-4946